EN DE
Watch Edesa Biotech Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Edesa Biotech Inc (EDSA) fair value: what the stock is really worth

As of Nov 11, 2026: fair value (intrinsic value) of Edesa Biotech Inc stock $1.12, price $2.22, that is 49.5% below the price, quality 51 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · Home Canada · ISIN CA27966L3065

EB Edesa Biotech Inc logo Thin data Nov 10, 2026

Edesa Biotech Inc

EDSA · US
Stretched Valuation

Our calculation puts a fair price 50% below what the stock costs today.

Positive coverage
Quality 51/100
Fair value $1.12 · Strongly overvalued
Weak Growth (revenue 5y −79.2 %/yr in USD)
Negative free cash flow
Trails peers (2/6)
Narrow moat 3/100 · thin data
Thin data
Estimate
Watch Edesa Biotech Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$83.44 $0.8000 Fair Value $1.12 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range $0.8000 – $83.44 · fair‑value band $0.8400 – $1.40 · the $2.22 price screens above the $1.12 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Edesa Biotech in your weekly email

Every Wednesday you see whether Edesa Biotech is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases.

Show moreShow less

It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis.

The company develops EB07, a monoclonal antibody, which is in a Phase 2 clinical study for the treatment of pulmonary fibrosis; and EB06, a human monoclonal antibody candidate that binds to chemokine ligand 10 (CXCL10) and inhibits the interaction of CXCL10 with its receptors, CXCR3A, and CXCR3B. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions.

The company was founded in 2015 and is headquartered in Markham, Canada.

Stock analysis

Edesa Biotech Inc (EDSA) currently trades at $2.22, while our estimate is $1.12, 50% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $0.8400 (bear) to $1.40 (bull), the price of $2.22 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 51/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Edesa Biotech Inc reported revenue of $0 in FY2025 versus $500 in FY2021. Reported net income was −$7.2M in FY2025.

Key figures

Market cap $34.6M Micro · EPS (TTM) $−1.67 · Return on equity −123% · Return on assets (EBIT) −133% (5-year average) · Revenue (TTM) $500 · Free cash flow −$7.3M · Net cash $10.8M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 3 out of 100 (low confidence).

What moves the price

The share trades about 88% below its 52-week high and 178% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −50%, EDSA screens richer than that median.

Fair Value

Bear $0.8400 Fair Value $1.12 Bull $1.40
Price $2.22 · Downside -49.5%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 51/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 75
Are margins and returns getting better?
Cashflow 67
Do the profits arrive as real cash?
Financial strength 100
Debt, balance sheet and risk of trouble
Investment 62
Does it invest with discipline instead of growing at any price?
Low Volatility 22
How calm the share price moves, does not count
Price momentum 30
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 37
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

  • BuyPardeep NijhawanChief Executive Officer, Director, 10% owner6× since Feb 26, 2026: 84,571 shares, avg. $2.72$229,882Mar 10, 2026
  • BuyMichael J BrooksPresident2,000 shares at $1.57$3,140Feb 26, 2026

Plus 17 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 10, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−99.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−86.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−79.2%
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−49.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−386.0% (2016) → −4,736,266.4% (2021)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

EDSA screens overvalued: fair value 50% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Earlier news

News mood ⓘNews mood, the average tone of recent news (28 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Positive
Recent news coverage is more positive than average.

Compare Edesa Biotech Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 848 stocks

Beats the industry median on 2/5 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 51 · Top 25%
Fair Value upside −49.5% · Bottom 25%
Profitability
Return on assets −53.1% · Bottom 25%
Operating margin (12 months) 0.0% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 2.78× · Pricier than median

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $959.41 $1,275 +33% vs EDSA
Vertex Pharmaceuticals Incorporated VRTX $547.03 $602.68 +10% vs EDSA
Samsung Biologics Co 207940 1,430,000 KRW 1,573,000 KRW +10% vs EDSA
Genmab A/S GMAB kr 3,561 kr 3,880 +9% vs EDSA
argenx SE ARGX $977.58 $908.40 −7% vs EDSA
CSL Limited CSL A$204.54 A$181.40 −11% vs EDSA
Moderna, Inc MRNA $248.69 $158.70 −36% vs EDSA
BeOne Medicines AG 6160 HK$251.80 HK$152.80 −39% vs EDSA
Celltrion, Inc 068270 207,000 KRW 74,945 KRW −64% vs EDSA
Royalty Pharma plc RPRX $70.01 $19.01 −73% vs EDSA

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Average Down CalculatorFree calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Edesa Biotech Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Edesa Biotech Inc Fair Value". https://www.fairvalue-calculator.com/stock/EDSA

Frequently asked questions

Is Edesa Biotech Inc (EDSA) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $1.12 versus a price of $2.22, about 50% lower (overvalued).
What is the fair value of EDSA?
Our estimate for Edesa Biotech Inc is $1.12 (as of Nov 10, 2026), built from audited fundamentals. The current price: $2.22.
What is the quality score of EDSA?
Edesa Biotech Inc has a Quality Score of 51/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Edesa Biotech Inc (EDSA)?
Our calculated price target is the estimate of $1.12 (as of Nov 10, 2026). Cautious scenario $0.8400, optimistic scenario $1.40. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Edesa Biotech Inc stock forecast for 2026?
Our estimate puts fair value at $1.12, about 50% lower versus a price of $2.22 (overvalued). Cautious scenario $0.8400, optimistic scenario $1.40. The calculation is refreshed regularly with new filings.
What is the revenue of Edesa Biotech Inc (EDSA)?
Edesa Biotech Inc reported trailing-twelve-month revenue of about $500 (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Edesa Biotech Inc (EDSA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Edesa Biotech Inc it is $1.12 per share (as of Nov 10, 2026), against a price of $2.22.
Is Edesa Biotech Inc stock overvalued or undervalued in 2026?
As of Nov 10, 2026, EDSA trades above its calculated fair value: price $2.22, fair value $1.12, a gap of about −50% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of EDSA?
No. The price is what the market pays today ($2.22); the fair value is what the company's own numbers justify ($1.12). For Edesa Biotech Inc the two are $1.10 per share apart. That gap is exactly why we show both numbers side by side.
How much is Edesa Biotech Inc worth?
The market values Edesa Biotech Inc at about $34.6M (market capitalisation, as of Nov 10, 2026). Per share that is $2.22; our models calculate a fair value of $1.12 per share.
What do the bullish and bearish scenarios say about EDSA?
Our models span a range for Edesa Biotech Inc: cautious scenario $0.8400, base $1.12, optimistic $1.40 per share (as of Nov 10, 2026, price $2.22). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Edesa Biotech Inc (EDSA)?
Balance-sheet figures for Edesa Biotech Inc (as of Nov 10, 2026): return on equity −122.9%. They feed the Quality Score of 51/100, which measures business quality independently of the share price.
How far is EDSA from its 52-week high?
Edesa Biotech Inc trades at $2.22, about 88% below its 52-week high of $18.28 and 178% above the low of $0.8000 (as of Nov 11, 2026). Distance from the high says nothing about value: that is what the fair value of $1.12 is for.
Which stocks are comparable to Edesa Biotech Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Edesa Biotech Inc stock attractive at the current price?
The data as of Nov 10, 2026: price $2.22, calculated fair value $1.12 (−50%), Quality Score 51/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0% above its aggregate fair value. Edesa Biotech Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Edesa Biotech Inc (EDSA)?
The closing price on Nov 11, 2026 was $2.22. Our estimate is $1.12, about 50% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Edesa Biotech Inc right now?
The price sits above even our optimistic bull case ($1.40). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (51/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of Edesa Biotech Inc

How large is the market capitalisation of Edesa Biotech Inc (EDSA)?
The market capitalisation of Edesa Biotech Inc is $34.6M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Edesa Biotech Inc (EDSA)?
Earnings per share at Edesa Biotech Inc are $−1.67. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Edesa Biotech Inc (EDSA)?
The return on equity (ROE) of Edesa Biotech Inc is −123% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Edesa Biotech Inc (EDSA)?
On an EBIT basis the return on assets of Edesa Biotech Inc is −133% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Edesa Biotech Inc (EDSA) generate?
The free cash flow of Edesa Biotech Inc is −$7.3M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Edesa Biotech Inc (EDSA) hold?
Edesa Biotech Inc holds more cash than debt, $10.8M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Edesa Biotech Inc in the live analysis

One click puts Edesa Biotech Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.